Asthma Treatment Update: Benralizumab's Impact on Corticosteroid Use

How the SHAMAL Trial Offers New Hope for Severe Eosinophilic Asthma Patients

Feb 09, 2024

∙ Paid

An abstract representation of eosinophilic asthma, featuring a silhouette of human lungs filled with swirling patterns of red and white, symbolizing inflammation and the accumulation of eosinophils. The background is a gradient of soothing blues to represent air and breath, with a few scattered white dots to illustrate the concept of air flow being obstructed by the condition. This image aims to convey the complexity and severity of eosinophilic asthma in a visually engaging manner, emphasizing the challenges in air flow and the targeted approach needed for treatment.

Topline:

A groundbreaking SHAMAL phase IV trial reveals that Benralizumab (Fasenra) enables severe eosinophilic asthma patients to safely reduce high-dose inhaled corticosteroids without compromising asthma control, offering new insights for healthcare providers and patients alike.

Study Details:

Keep reading with a 7-day free trial

Subscribe to Just Healthcare to keep reading this post and get 7 days of free access to the full post archives.